Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Correspondencia: gmemiinv@gmail.com
Angélica Torres A.
Introducción
Diagnóstico
Tratamiento
Tabla 1.
Fda
Embaraz
Fármaco Lactancia Teratogénico
Riesgo o
fetal
Glucosidos
cardiacos
Atraviesa la
barrera
placentaria
Con
precaución se Toxicidad se
Digoxina C + No
excreta en la asocia a
leche muerte fetal.
Clase Ia
No Trombocitopeni
Quinidina C + No
recomendada a
Corto No Síndrome
Procainamida C No
tiempo recomendada lupus-like
Pocos No Contracciones
Disopiramida C No
datos recomendada uterinas
Clase Ic
No Datos
Flecainide C + No
recomendada insuficientes
Clase II
Con
precaución
No
se excreta en
la leche
Beta-
bloqueadores
adrenérgicos Pasan la
Propanolol C + placenta
No
restricción del
recomendad No
Metoprolol C + crecimiento
a. Se excreta
intrauterino,
en leche
Esmolol C + depresión
respiratoria
neonatal,
bradicardia,
No No hipoglucemia.
recomendad
a. Se
desconoce
excreción
Clase III
No Torsade de
recomendad points,
Sotalol No
B + a. Se excreta grandes
en leche cantidades en
leche materna.
Tiroidopatia,
bradicardia,
restricción de
No
crecimiento,
recomendad
NO ?? prematuridad,
Amiodarona D a. Se excreta
complicaciones
en leche
del desarrollo
neurológico.
No
recomendad
Bloqueo
a. Se excreta
Clase IV cardiaco,
en leche.
No hipotensión.
Verapamil C +
Diltiazem C + No
No hay No hay
recomendad
datos información.
a. Se excreta
en leche
Cardioversión eléctrica
Terapia antitrombótica
Conclusión
Referencias:
1. Mcnulty JH. Arrhythmias in Pregnancy. Cardiol Clin. 2012;30(3):
425–434.
2. European Heart Rhythm Association; European Association for
Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY,
Schotten U, Guidelines for the management of atrial
fibrillation: the Task Force for the Management of Atrial
Fibrillation of the European Society of Cardiology (ESC).
Europace. 2010 Oct;12(10):1360-1420.
3. Secretaria de Salud. Guía de Práctica clínica Diagnostico y
tratamiento de la fibrilación auricular. México; Catalogo
maestro. 2011;SS-014-08.
4. Saoudi N, Cosío F, Waldo A, et al. A classification of atrial
flutter and regular atrial tachycardia according to
electrophysiological mechanisms and anatomical bases; a
Statement from a Joint Expert Group from The Working Group
of Arrhythmias of the European Society of Cardiology and the
North American Society of Pacing and Electrophysiology. Eur
Heart J. 2001; 22(14):1162-1682.
5. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006
guidelines for the management of patients with atrial
fibrillation: full text: a report of the American College of
Cardiology/American Heart Association Task Force on practice
guidelines and the European Society of Cardiology Committee
for Practice Guidelines (Writing Committee to Revise the 2001
guidelines for the management of patients with atrial
fibrillation) developed in collaboration with the European
Heart Rhythm Association and the Heart Rhythm Society.
Europace. 2006;8 (9):651-745.
6. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS
focused update on the management of patients with atrial
fibrillation (Updating the 2006 Guideline): a report of the
American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll
Cardiol. 2011;57(2):223-42.
7. Trappe HJ. Emergency therapy of maternal and fetal
arrhythmias during pregnancy. J Emerg Trauma Shock.
2010;3(2):153–9.
8. Gómez Flores JR, Márquez MF. Arritmias en el embarazo:
¿Cómo y cuándo tratar? Arch. Cardiol. Méx. 2007,77(2); 24-31.
9. Bernal O, Moro C. Arritmias cardiacas en la mujer. Rev Esp
Cardiol. 2006;59(6):609-18.
10. Sengheiser CJ, Channer KC. Rare disase Recurrent atrial
flutter and fibrillation in pregnancy BMJ Case Rep. 2011;2011.
11. Knotts RJ, Garan H. Cardiac arrhythmias in pregnancy. Semin
Perinatol. 2014;38(5):285-8.
12. Greer, IA. Thrombosis in pregnancy: maternal and fetal
issues. Lancet. 1999;353(9160):1258-65.
13. Goland S, Elkayam U. Anticoagulation in Pregnancy. Cardiol
Clin. 2012;30(3): 395–405.
14. Sommerkamp SK, Gibson A. Cardiovascular Disasters in
Pregnancy. Emerg Med Clin North Am. 2012;30(4):949-59.
15. VerNooy RA, Mounsey JP. Antiarrhythmic drug therapy of
atrial fibrillation. Cardiol Clin. 2004 Feb;22(1):21-34.
16. Frishman WH, Elkayam U, Aronow WS. Cardiovascular Drugs
in Pregnancy. Cardiol Clin. 2012;30(3):463–91.
17. Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a
correctable cause of “idiopathic” atrial fibrillation. Am J Cardiol.
1979;44(1):9-12.
18. Tan HL, Lie KI. Treatment of tachyarrhythmias during
pregnancy and lactation. Eur Heart J. 2001;22(6):458-64.
19. Regitz-Zagrosek V, Gohlke-Bärwolf C, Iung B, Pieper PG.
Management of cardiovascular diseases during pregnancy.
Curr Probl Cardiol. 2014;39(4-5):85-151
20. Gowda RM, Khan IA, Mehta NJ, Vasavada BC, Sacchi TJ.
Cardiac arrhythmias in pregnancy: clinical and therapeutic
considerations. Int J Cardiol. 2003;88(2-3):129-133.
21. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011
ACCF/AHA/HRS focused update on the management of
patients with atrial fibrillation (update on dabigatran): a report
of the American College of Cardiology Foundation/American
Heart Association Task Force on practice guidelines. J Am Coll
Cardiol. 2011;57(11):1330-7
22. Bapat P, Kedar R, Lubetsky A, et al. Transfer of dabigatran
and dabigatran etexilate mesylate across the dually perfused
human placenta. Obstet Gynecol. 2014;123(6):1256-61.
Contacto